Arsenic Trioxide in Treating Patients With Urothelial Cancer

NCT00009867 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Transitional Cell Carcinoma of the Bladder
Ureter Cancer

Interventions

DRUG: arsenic trioxide

Sponsor

National Cancer Institute (NCI)